Detalhe da pesquisa
1.
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
Br J Dermatol
; 188(2): 208-217, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763879
2.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Br J Dermatol
; 187(3): 338-352, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484697
3.
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.
Exp Dermatol
; 30(11): 1650-1661, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003519
4.
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
J Am Acad Dermatol
; 85(4): 847-853, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090959
5.
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
J Am Acad Dermatol
; 85(1): 62-70, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33600915
6.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
J Am Acad Dermatol
; 83(3): 839-846, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344071
7.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10143): 222-231, 2018 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30043749
8.
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
J Am Acad Dermatol
; 80(4): 913-921.e9, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29410014
9.
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Nephrol Dial Transplant
; 33(11): 1950-1959, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481660
10.
Drotrecogin alfa (activated) in adults with septic shock.
N Engl J Med
; 366(22): 2055-64, 2012 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22616830
11.
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
J Clin Endocrinol Metab
; 108(12): 3122-3134, 2023 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390454
12.
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.
Crit Care
; 15(1): R23, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21241489
13.
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).
Crit Care
; 14(6): R229, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21176144
14.
Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry.
Crit Care
; 14(3): R102, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20525247
15.
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
JAMA Dermatol
; 156(12): 1333-1343, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001140
16.
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.
Crit Care
; 13(3): R103, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19566927
17.
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
Crit Care
; 12(2): R45, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18394162
18.
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
Crit Care
; 12(5): R117, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18786266
19.
Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
Clin Pharmacol Ther
; 104(2): 364-373, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29134648
20.
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
J Clin Invest
; 128(7): 3041-3052, 2018 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29649002